Vertex, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher David Young
- Full Time Employees
- 2,100
- Sector
- Technology
- Industry
- Software - Application
- Address
- 2301 Renaissance Boulevard King of Prussia PA United States of America 19406
- IPO Date
- Jul 29, 2020
- CIK
- 0001806837
- Website
- vertexinc.com
- Similar Companies
- Business
- Vertex, Inc. is a technology company primarily engaged in providing tax compliance, tax automation, and related software solutions. The company offers a comprehensive suite of products and services including indirect tax software for managing sales and use tax, value-added tax (VAT), goods and services tax (GST), and other transactional taxes globally; automated tax determination software; tax data management solutions; cloud-based and on-premise tax compliance software; and integrated tax engines for enterprise resource planning (ERP) systems. Vertex’s product portfolio supports a range of industries including retail, manufacturing, financial services, and telecommunications, serving customers worldwide. The company also provides implementation, consulting, and support services to help businesses comply with evolving tax regulations. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, Vertex operates internationally with offices and clients across North America, Europe, and Asia. Recently, Vertex has expanded its capabilities through strategic partnerships and new product launches aimed at enhancing its global tax compliance automation offerings. In the past 1-2 years, the company has focused on advancing its cloud-based tax solutions to better address digital tax complexities and cross-border tax compliance challenges. Vertex continues to invest in technology upgrades and integrations to support multinational corporations’ growing needs, positioning itself as a leader in the tax technology industry. These developments reflect Vertex’s commitment to innovation and broadening its market reach, underscoring its role in delivering advanced tax software solutions to help businesses navigate increasingly complex global tax landscapes. The company leverages its proprietary tax engine and extensive tax content database to deliver precise and scalable tax management solutions. Vertex is recognized for its strong customer support and technology-driven approach, targeting large enterprises and mid-market companies needing comprehensive tax automation and compliance tools. This dynamic business environment and Vertex’s expansions highlight the company’s strategic focus on maintaining leadership in the evolving tax technology sector through continuous product enhancement and global operational growth.
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Vertex to Announce Second Quarter 2026 Financial Results on Monday, August 3, 2026
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
Vertex's Crinetics Deal Balances Growth with Integration Risk
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Crinetics shares surge after Vertex agrees to $10B cash buyout
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex Pharma Makes A $10 Billion Deal; Biotech Stock Doubles
Vertex to buy Crinetics in $10 billion deal
Vertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia